News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Amarex Clinical Research guides its client to phase II of FDA trials
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
It is developing the drug candidate to potentially treat immunological diseases
Survey findings released in advance of World Lupus Day on May 10
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Subscribe To Our Newsletter & Stay Updated
